Quantum-Si incorporated QSI R2K
Healthcare · Medical Devices · United States
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-based solution that automates data analysis workflows and visualizes the sequencing results. The company was founded in 2013 and is headquartered in Branford, Connecticut.
READ MORE ›$1.19
-29.17% 1Y
Market & Price
Market Cap
$259.13M
Current Price
$1.19
High / Low (52W)
$2.63 / $0.71
Beta
3.16
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.92
Price to Book
1.29
P/S
139.92
EV/EBITDA
-1.49
Dividend Yield
-
Profitability & Returns
ROCE
-43.74%
ROE
-46.38%
ROA
-24.76%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.10
EPS (TTM)
$-0.50
Balance Sheet & Liquidity
Debt/Equity
1.85
Quick Ratio
11.91
Current Ratio
12.60
Debt
$3.71M
Total Assets
$245.61M
Current Assets
$175.86M
Working Capital
$152.84M
Ownership
Promoter Holding
10.51%
Chg in Prom Hold
-
FII / Inst Holding
29.93%
Chg in FII Hold
-
Financial Snapshot
Enterprise Value
$135.51M
Total Revenue (TTM)
$1.85M
EBITDA
$-91.23M
Free Cash Flow
$-45.93M
Operating Cash Flow
$-94.20M
Shares Outstanding
197.82M
Gross Margin
40.01%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-
Profit 5Y
7.83%
Revenue (YoY)
-69.40%
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- Trading 54.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QSI Quantum-Si incorporated R2K | 1.19 | - | $259.13M | - | -43.74% | -46.38% | - | 7.83% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 254.00K | 205.00K | 223.00K | 457.00K | 622.00K | - | 842.00K | 591.00K | 552.00K | 451.00K | 258.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 356.00K | 240.00K | 358.00K | 329.00K | 184.00K |
| Gross Profit | - | - | - | - | - | - | 0 | 0 | 0 | 124.00K | 78.00K | 108.00K | 269.00K | 354.00K | - | 486.00K | 351.00K | 194.00K | 122.00K | 74.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.60M | 27.11M | 24.59M | 21.22M | 24.13M |
| Operating Income | - | -8.20M | -8.55M | -11.78M | -32.16M | -25.18M | -27.14M | -30.20M | -27.66M | -29.22M | -26.89M | -27.18M | -23.36M | -26.45M | - | -25.11M | -26.76M | -24.40M | -21.09M | -24.05M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -24.20M | -25.57M | -23.22M | -19.92M | -22.83M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.18M | -28.82M | -35.68M | -17.60M | -21.79M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.00K | 20.00K | 19.00K | 8.00K | -122.00K |
| Net Income | -10.31M | -8.20M | -8.56M | -11.78M | -35.70M | -18.09M | -35.17M | -32.41M | -31.71M | -23.61M | -25.57M | -24.73M | -19.47M | -23.10M | - | -19.19M | -28.84M | -35.70M | -17.61M | -21.67M |
| Diluted EPS | - | -1.53 | -1.60 | -2.13 | -0.97 | -0.13 | -0.25 | -0.23 | -0.23 | -0.17 | -0.18 | -0.17 | -0.14 | -0.16 | - | -0.11 | -0.16 | -0.17 | -0.08 | -0.10 |
| R&D Expense | - | 6.59M | 6.66M | 7.97M | 13.11M | 11.10M | 18.77M | 18.46M | 16.68M | 18.17M | 15.83M | 16.59M | 12.10M | 14.38M | 16.17M | 13.72M | 15.21M | 13.88M | - | 14.49M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 1.08M | 3.06M | 2.44M |
| Cost of Revenue | - | - | - | 0 | 594.00K | 1.46M | 1.28M |
| Gross Profit | - | - | - | 0 | 488.00K | 1.60M | 1.15M |
| Operating Expenses | - | - | - | 114.36M | 111.66M | 110.18M | 98.51M |
| Operating Income | -36.62M | -36.69M | - | -114.36M | -111.17M | -108.58M | -97.36M |
| EBITDA | - | - | - | -111.77M | -107.02M | -103.98M | -92.91M |
| Interest Expense | - | - | 5.00K | 0 | 0 | - | - |
| Pretax Income | - | - | - | -132.44M | -95.96M | -100.95M | -101.28M |
| Tax Provision | - | - | - | 0 | 0 | 56.00K | 58.00K |
| Net Income | -35.79M | -36.61M | - | -132.44M | -95.96M | -101.01M | -101.34M |
| Diluted EPS | -6.95 | -6.84 | - | -0.95 | -0.68 | -0.71 | -0.51 |
| R&D Expense | 28.10M | 27.55M | 46.58M | 72.06M | 67.03M | 59.64M | 53.76M |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -69.40% |
Compounded Profit Growth
| 5 Years: | 7.83% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -29.17% |
| 6 Months: | -11.85% |
| 3 Months: | +24.48% |
| 1 Month: | +37.57% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Jun 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 40.59M | - | 391.49M | 298.25M | 247.87M | 245.61M |
| Current Assets | - | - | - | - | - | 358.18M | 266.31M | 218.01M | 175.86M |
| Cash & Equivalents | - | - | - | 36.91M | - | 84.32M | 133.86M | 49.24M | 21.64M |
| Inventory | - | - | - | - | - | 0 | 3.94M | 4.07M | 3.20M |
| Receivables | - | - | - | - | - | 0 | 368.00K | 1.33M | 561.00K |
| Total Liabilities | - | - | - | 4.50M | - | 32.78M | 26.63M | 32.45M | 25.38M |
| Current Liabilities | - | - | - | 2.75M | - | 15.71M | 11.61M | 18.19M | 23.02M |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 17.45M | 15.30M | 12.95M | 4.17M |
| Total Equity | -92.14M | -125.10M | 0 | -159.72M | - | 358.71M | 271.62M | 215.42M | 220.23M |
| Shares Outstanding | - | - | - | - | - | 139.94M | 141.77M | 166.89M | 216.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -30.71M | -32.57M | - | -90.56M | -94.04M | -87.80M | -94.72M |
| Investing Cash Flow | -1.24M | -461.00K | - | 137.19M | 143.43M | -32.67M | -28.32M |
| Financing Cash Flow | 18.22M | 37.01M | - | 1.91M | 149.00K | 35.88M | 95.42M |
| Capital Expenditure | -1.24M | -461.00K | - | -10.74M | -5.27M | -4.64M | -2.52M |
| Free Cash Flow | -31.95M | -33.03M | - | -101.30M | -99.31M | -92.44M | -97.23M |
| Net Change in Cash | - | - | - | 48.53M | 49.54M | -84.59M | -27.61M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 45.1% | 52.3% | 47.3% |
| Operating Margin % | - | - | - | - | -10,274.6% | -3,550.6% | -3,996.7% |
| Net Margin % | - | - | - | - | -8,868.8% | -3,303.0% | -4,160.1% |
| ROE % | 28.6% | 22.9% | - | -36.9% | -35.3% | -46.9% | -46.0% |
| ROCE % | - | -97.0% | - | -30.4% | -38.8% | -47.3% | -43.7% |
Shareholding Pattern
Insiders
10.51%
Institutions
29.93%
Public Float
33.45%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 6.78% | 13.41M | $15.96M |
| 2 | Vanguard Capital Management LLC | 3.55% | 7.02M | $8.36M |
| 3 | ARK Investment Management, LLC | 3.48% | 6.88M | $8.19M |
| 4 | Sumitomo Mitsui Trust Group, Inc. | 2.22% | 4.39M | $5.23M |
| 5 | Amova Asset Management Americas Inc | 2.22% | 4.39M | $5.23M |
| 6 | Geode Capital Management, LLC | 1.94% | 3.84M | $4.56M |
| 7 | State Street Corporation | 1.91% | 3.77M | $4.49M |
| 8 | AQR Capital Management, LLC | 1.21% | 2.39M | $2.85M |
| 9 | UBS Group AG | 0.86% | 1.70M | $2.03M |
| 10 | Vanguard Portfolio Management LLC | 0.77% | 1.52M | $1.81M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QSI
No recent headlines available.